What Octreotide is
Octreotide is a somatostatin analog that targets somatostatin receptor signaling in approved clinical contexts.
Octreotide is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it is a high-trust contrast point: a peptide analog with a real label and defined medical use.
The useful starting point is to separate the molecule itself from the internet story around it. It is a serious approved peptide drug, not a wellness peptide.
Why people keep looking it up
People know octreotide as a clinical somatostatin analog.
Octreotide mimics somatostatin receptor signaling in specific medical contexts.
Octreotide tends to stay in the conversation because it touches a familiar public theme: somatostatin analog, sstr receptors, and neuroendocrine. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved labeling defines the claims. Internet extrapolation should stay out of it.
Human clinical evidence and official labels support specific indications.
Mechanistic rationale follows somatostatin receptor pharmacology.
Why this page carries the current tier: Approved peptide analog with official label trail.
The current seed trail for Octreotide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Claim scope should stay tied to official labels and clinical contexts.
FDA-approved octreotide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Octreotide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Octreotide is CID 448601. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 448601
- Formula
- C49H66N10O10S2
- Molecular weight
- 1019.2
- InChIKey
- DEQANNDTNATYII-OULOTJBUSA-N
Matched synonyms include Octreotide, 83150-76-9, Octreotida, Octreotidum, RWM8CCW8GP, SMS-201-995, SMS995, SMS-995.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Octreotide returns 322 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Octreotide returns 12655 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Octreotide Acetate
- Generic names
- OCTREOTIDE ACETATE
- Routes
- INTRAVENOUS, SUBCUTANEOUS
- Application numbers
- ANDA075957
Indications and usage. 1 INDICATIONS AND USAGE Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For th...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Cardiac Function Abnormalities : Increased risk for higher degree of atrioventricular blocks. Consider cardiac monitoring in patients receiving octreotide acetate injection intravenously. Bradycardia, arrhythmias, or conduction abnormalities may occur. Use with caution in at-risk patients. Dosage adjustment of cardiac medications may be necessary. ( 5.1 ) Cholelithiasis and Complications o...
Contraindications. 4 CONTRAINDICATIONS Sensitivity to this drug or any of its components. Sensitivity to this drug or any of its components. ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.